Share your thoughts on this presentation with #IAS2019

Slides:



Advertisements
Similar presentations
"3 by 5" progress December 2005 Progress on global access to HIV antiretroviral therapy | 12 April |2 | Antiretroviral therapy coverage in low-
Advertisements

High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa – Implications for HIV and TB Treatment Programs Kogieleum Naidoo on behalf.
1 Voriconazole NDAs and Empiric Antifungal Therapy of Febrile Neutropenic Patients Study 603 John H. Powers, M.D. Medical Officer Division.
Ending AIDS by 2030 World AIDS Day Commemoration Addis Ababa, Ethiopia, 25 November 2014.
10 year Roadmap by 2025 David W. Denning President GAFFI The University of Manchester.
A cost-effectiveness evaluation of preventive interventions for HIV-TB in Sub-Saharan Africa (Tanzania): Relevance for neurological infections Lucie Jean-Gilles.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
1 July 2008 e Global summary of the AIDS epidemic, December 2007 Total33 million [30 – 36 million] Adults30.8 million [28.2 – 34.0 million] Women15.5 million.
It is estimated that over 50 per cent of the African population do not have access to modern health facilities and more than 60 per cent of people in rural.
COST-BENEFIT OF INTEGRATING CRYPTOCOCCAL ANTIGEN SCREENING AND PREEMPTIVE TREATMENT INTO ROUTINE HIV CARE Radha Rajasingham, David Meya, Melissa Rolfes,
Date of download: 5/28/2016 From: When to Start Antiretroviral Therapy in Resource-Limited Settings Ann Intern Med. 2009;151(3): doi: /
Hot Topics in Infectious Diseases Giuseppe Nunnari.
TB-HIV: What are we seeing in the communities? Mayowa Joel Treatment Action Movement (TAM), Nigeria.
Global summary of the HIV and AIDS epidemic, December 2003
Regional HIV and AIDS statistics and features, 2006
Worldwide availability and pricing of antifungal drugs
Global Action Fund for Fungal Infections
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
The role of secondary prophylaxis in the management of HIV-VL co-infection: 7-years experience from West Bengal Prof. Rama Prosad Goswami, Department.
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
Global summary of the AIDS epidemic, December 2007
Overview of Global HIV Epidemic
Participants 18year old+
Global summary of the HIV/AIDS epidemic, December 2003
The Effects of HIV/AIDS on the Immune System
Global summary of the AIDS epidemic, 2008
Global summary of the HIV/AIDS epidemic, December 2003
Estimated number of new HIV infections in young people
Global summary of the AIDS epidemic, 2008
CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS
The MSM and Trans Epidemic in the Caribbean
Aim: why study Human Geography?
William Burman Denver Public Health Tuberculosis Trials Consortium
HIV Opportunistic infections
HIV-associated TB mortality and blocks in the cascade
What is AIDS? HIV is a virus that attacks the immune system. If untreated, a person’s immune system will eventually be completely destroyed. AIDS refers.
Population Where is everybody?.
By: Dr Mirzaei.
Evidence for use of urinary LAM
Blood Culture (Bacterial, Mycobacterial & Fungal)
"3 by 5" progress December 2005.
8th Advances Against Aspergillosis international conference
Why histoplasma antigen detection should be included on the EDL ?
Global summary of the HIV and AIDS epidemic, December 2004
Cryptococcosis: Treatment outcome
Knowing your epidemic and knowing your response – maximising routinely collected data to measure and monitor HIV epidemics in sub-Saharan Africa Monitoring.
8th Advances Against Aspergillosis international conference
PCP: management of co-infection
Cryptococcal Immune Reconstitution Inflammatory Syndrome
Tuberculosis Global Epidemiology
Cryptococcosis: Epidemiology of cryptococcal disease
Advanced HIV diagnoses among gay and bisexual men in Australia Phillip Keen, Handan Wand, Hamish McManus, Muhammad Jamil, Skye McGregor, James.
Global summary of the AIDS epidemic, December 2007
PCP: management of co-infection
“The more there are suffering, then the more natural their sufferings appear. Who wants to prevent the fish in the sea from getting wet? Bertolt Brecht.
Cryptococcal Immune Reconstitution Inflammatory Syndrome
“The more there are suffering, then the more natural their sufferings appear. Who wants to prevent the fish in the sea from getting wet? Bertolt Brecht.
Western & Central Europe
When to START During an OI
Cryptococcosis: Epidemiology of cryptococcal disease
Global summary of the HIV/AIDS epidemic, December 2003
Cryptococcosis: Treatment outcome
Iman Wanis and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 What is the reality in the field? Survey.
Global summary of the HIV and AIDS epidemic, 2005
Global Summary of the HIV and AIDS Epidemic December 2004
Contents - HIV global slides
Children (<15 years) estimated to be living with HIV as of end 2005
Global summary of the HIV and AIDS epidemic, 2005
TB-HIV/AIDS Co-Infection Coordination among Programs
HIV/AIDS In Botswana.
Presentation transcript:

Share your thoughts on this presentation with #IAS2019 AIDS-related Mycoses: Cryptococcus, Histoplasma, and other Endemic Mycoses Andrej Spec, MD, MSCI Washington University In St Louis School of Medicine @FungalDoc Share your thoughts on this presentation with #IAS2019

Disclosure: Andrej Spec, M.D., MSCI Date: 7/23/2019 Andrej Spec, MD, MSCI has financial interests to disclose. Potential conflicts of interest have been resolved. Research Support / Grants Consulting/Honoraria NIH Astellas Scynexis MiraVista IMMY Cidara Amplyx Viamet Astellas Minnetronix Mayne Scynexis

Methods PubMed search in English using the MeSH database All searches include the fungus MeSH term AND "HIV"[Mesh] Limited to humans and last 5 years Supplemented by searches through the top 10 general medicine and ID journals (Based on Impact Factor) Articles selected using Altmetric score, and filtered on relevance

Cryptococcus

The Global Burden of Cryptococcus (Modeling) Average global incidence amongst PLWH with cd4<100 cells/ml is 6% This varies significantly between areas (~2-15%) Global estimate is 278,000 (95% CI 195,500–340,600) infections 181,100 (95% CI 119,400–234,300) deaths 73% of cases occur in Sub-Saharan Africa Lancet Infect Dis 2017; 17: 873–81

Central America left out of Model Central America is poorly studied, possibly underrepresented Our still unpublished data from San Pedro Sula, Honduras suggests the rate might be higher than previously thought 28/221 (12.7%) positive in San Pedro Sula Lancet Infect Dis 2017; 17: 873–81

Enhanced Prophylaxis in CD4<100 Study performed in Sub-Saharan Africa, with high incidence of TB and Cryptococcus (but not histoplasmosis, which would be important in Latin America) Enhanced prophylaxis with CD4 <100 , additional: 12 weeks of INH 12 weeks of fluconazole 5 Days of azithromycin Resulted in Improved survival N Engl J Med 2017;377:233-45

Decrease Seen in Fungal Infections and TB N Engl J Med 2017;377:233-45

Mortality Benefit the Highest in Cryptococcus N Engl J Med 2017;377:233-45

The Cost Effectiveness of 5FC In Sub-Saharan Africa, mean increase in cost is $219 (US), with an 18.7% decrease in mortality In US, cost in the last 5 years has been around $27,000 per 14-day course FDA has approved 3 new generics in the past year, bringing down the cost 78% to $5,900 (still unreasonable) Shiri, Clin Infec Dis, 2019 Rajasingham, Clin Infec Dis, 2019

Short Duration of Liposomal Amphotericin Phase 2 RCT comparing: L-Amb 10 mg/kg on day 1 L-Amb 10 mg/kg on day 1 and 5 mg/kg on day 3 L-Amb 10 mg/kg on day 1, and 5 mg/kg on days 3 and 7 L-Amb 3 mg/kg for 14 days No difference in outcome (EFA) 10-week mortality 15-29% between groups Phase 3 RCT underway Clinical Infectious Diseases 2019;68(3):393–401

histoplasma

“Histoplasma Dethrones TB” Lancet Infect Dis 2018; 18: 1150–59

Uncovering the Iceberg in Colombia When clinicians are trained to look for histoplasmosis, there is a dramatic increase in diagnoses Introduction of the Histoplasma antigen test by the CDC has increased diagnoses in areas 7-fold J. Fungi 2019, 5, 51

The Effect of Earlier Diagnoses on Mortality in French Guiana J. Fungi 2019, 5, 51

Where are the Extra Cases Coming from? Am. J. Trop. Med. Hyg., 84(2), 2011, pp. 239–240 Sterling, CROI 2015, Abs #883

The Entry of Histoplasma LFA Initial CDC testing in 2009 created a limited time antigen test that could be deployed in low to middle income countries Spurred innovation with both MiraVista and IMMY commercial LFAs under development Anticipated sensitivity of 80-90% Below current EIA, but will dramatically improve current diagnostics Awareness raising in each country still required PLoS Negl Trop Dis. 2018 Oct; 12(10): e0006802.

Other endemic mycoses

Treatment of Talaromcyes N Engl J Med 2017;376:2329-40.

Driver of Outcome is EFA N Engl J Med 2017;376:2329-40.

Discovery of HIV-Related Emonsia in Italy and South Africa Histoplasma like infection Prominent skin findings Described as Emonsia No longer Emonisa Many of the species previously called Emonisa, that cause adiospiromycosis are reclassified into Emergomyces spp. Italian taxa (now Emergomyces pasteurianus) S African taxa (Emergomyces africanus) N Engl J Med 2013;369:1416-24.

Summary Cryptococcus and Histoplasma have high incidence Incidence is likely underappreciated Often misdiagnosed as TB or HIV-wasting Amphotericin still appears to be the most effective antifungal Novel strategies for dosing may overcome cost barriers 5FC is cost effective and the price is coming down Enhanced prophylaxis for people diagnosed with advanced disease

Thank you for your time @FungalDoc